tuneTypical Dose
2.4
Peptide
Semaglutide
Semaglutide
Evidence TierBWADA NOT PROHIBITED
watchEffect Window
Benefits typically separate from baseline after 8–16 weeks, with major outcomes by 24–68 weeks.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Semaglutide is a GLP-1 receptor agonist prescription medication used for type 2 diabetes and obesity. It reduces appetite and improves glycemic control through incretin signaling and slowed gastric emptying.
Large trials show substantial weight loss and major reductions in HbA1c, with improvements in blood pressure and lipid biomarkers. Evidence also supports reduced cardiovascular events in high-risk populations. Minority findings include improvements in fatty liver biomarkers and some obesity-related complications. Gastrointestinal side effects are common and dose titration influences tolerability and adherence.
GLP-1 receptor agonist that reduces appetite and caloric intake, supports glucose-dependent insulin signaling, and lowers cardiometabolic risk markers.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Percent body-weight reduction
- Glycemic control in T2D
- MACE reduction in selected high-risk populations
Secondary Outcomes
- Waist reduction
- Blood pressure improvement
- Reduction in appetite/craving reports
Safety
Contraindications and Interactions
Contraindications
- Personal/family history of MTC
- MEN2
- Severe known hypersensitivity
- Pregnancy (unless specific benefit-risk review)
- Severe gastroparesis
Side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Pancreatitis risk
Interactions
- Insulin
- Sulfonylurea
- Oral medications with narrow therapeutic index
Avoid if
- Concurrent GLP-1 RA use
- History of pancreatitis
- Active severe mood instability without treatment plan
- Unsupervised weight-loss-only cycling
Evidence
Study-level References
semaglutide-SRC-001Randomized controlled trial.
Sourceopen_in_newWilding JP et al. 2021. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 384(11): 989-1002. [PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
Population: Adults with BMI ≥30 or BMI ≥27 + comorbidity; no diabetes.
Dose protocol: Semaglutide 2.4 mg once weekly vs placebo + lifestyle support for 68 weeks.
Key findings: Mean weight change difference and strong responder profile relative to placebo; GI discontinuations noted.
Notes: Core weight-efficacy anchor trial in semaglutide obesity program.
Paper content
Mean weight change difference and strong responder profile relative to placebo; GI discontinuations noted.
semaglutide-SRC-002Randomized controlled trial.
Sourceopen_in_newDavies M et al. 2021. "Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)." Lancet 397(10278): 971-984. [PMID: 33667417](https://pubmed.ncbi.nlm.nih.gov/33667417/)
Population: Adults with overweight/obesity plus type 2 diabetes.
Dose protocol: 2.4 mg vs 1.0 mg vs placebo weekly for 68 weeks.
Key findings: 2.4 mg showed greater weight and glycemic improvement than 1.0 mg/placebo.
Notes: Confirms dose-response behavior at obesity-vs-diabetes-strength endpoints.
Paper content
2.4 mg showed greater weight and glycemic improvement than 1.0 mg/placebo.
semaglutide-SRC-003Randomized controlled trial.
Sourceopen_in_newRubino D et al. 2021. STEP 3 trial in adults with overweight/obesity with intensive behavioral therapy. JAMA. 10.1001/jama.2021.3224. [JAMA abstract](https: //jamanetwork.com/journals/jama/article-abstract/2777025)
Population: Adults with overweight/obesity, no diabetes.
Dose protocol: 2.4 mg weekly, with initial low-calorie phase + behavioral therapy.
Key findings: ~16.0% mean weight loss at week 68 vs 5.7% placebo; larger gains in large-category responders.
Notes: One of the higher-intensity behavioral augmentation trials.
Paper content
~16.0% mean weight loss at week 68 vs 5.7% placebo; larger gains in large-category responders.
semaglutide-SRC-004Randomized controlled trial (withdrawal).
Sourceopen_in_newRubino D et al. 2021. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Trial." JAMA. 10.1001/jama.2021.3224. [PubMed: 33755728](https://pubmed.ncbi.nlm.nih.gov/33755728/)
Population: Adults with overweight/obesity after 20-week semaglutide run-in.
Dose protocol: 2.4 mg weekly run-in then continue semaglutide vs switch-to-placebo for 48 weeks.
Key findings: Continued semaglutide drove sustained additional loss vs replacement with placebo.
Notes: Strong support for maintenance planning and relapse prevention needs.
Paper content
Continued semaglutide drove sustained additional loss vs replacement with placebo.
semaglutide-SRC-005Randomized controlled trial (CV outcomes).
Sourceopen_in_newMarso SP et al. 2016. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." N Engl J Med. 375(19): 1834-1844. [PMID: 27633186](https://pubmed.ncbi.nlm.nih.gov/27633186/)
Population: Adults with T2D and high CV/renal risk.
Dose protocol: 0.5 mg and 1.0 mg weekly.
Key findings: Hazard ratio for MACE 0.74 vs placebo; significant CV reduction signals and mixed retinal safety signals in rapid responders.
Notes: Cardiometabolic proof-of-concept but in a higher-risk diabetes cohort.
Paper content
Hazard ratio for MACE 0.74 vs placebo; significant CV reduction signals and mixed retinal safety signals in rapid responders.
semaglutide-SRC-006Large outcome trial with long-term follow-up.
Sourceopen_in_newWilding JP et al. 2024/2025 Select trial report. "Semaglutide in overweight or obesity, long-term outcomes." Lancet/NEJM-derived follow-up report. [PMID: 38740993](https://pubmed.ncbi.nlm.nih.gov/38740993/)
Population: Overweight/obese adults with established CV disease, no diabetes required.
Dose protocol: 2.4 mg style long-term regimen + background standard care, up to 208 weeks.
Key findings: Durable risk reduction signal and persistent weight effects versus placebo over multiyear follow-up.
Notes: Provides durability context beyond classic 68-week weight trials.
Paper content
Durable risk reduction signal and persistent weight effects versus placebo over multiyear follow-up.
semaglutide-SRC-007Post-hoc pooled analysis.
Sourceopen_in_newMultiple CV safety analyses combining SUSTAIN and PIONEER outcomes. "Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk." Diabetes Obes Metab. [PMID: 31903692](https://pubmed.ncbi.nlm.nih.gov/31903692/)
Population: Glycemic trial populations across risk subgroups.
Dose protocol: SUSTAIN and PIONEER dosing strata.
Key findings: MACE reduction trend generally consistent, though subgroup certainty varies.
Notes: Useful as supportive mechanistic/consistency source.
Paper content
MACE reduction trend generally consistent, though subgroup certainty varies.
semaglutide-SRC-008Regulatory labeling / pooled trial synthesis.
Sourceopen_in_newFDA/DailyMed prescribing information for WEGOVY (semaglutide, injection and tablets). [FDA report](https: //fda.report/DailyMed/ee06186f-2aa3-4990-a760-757579d8f77b)
Population: Approved-use patient populations.
Dose protocol: Product-specific dosing and contraindication framework.
Key findings: Provides practical dosing, contraindications, warnings, and interaction rules.
Notes: Not a trial but essential for operational safety envelope.
Paper content
Provides practical dosing, contraindications, warnings, and interaction rules.
semaglutide-SRC-009Randomized, mechanism-focused clinical trial.
Sourceopen_in_newDiabetes, obesity, and appetite mechanistic trial. "The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity." Diabetes Obes Metab. 2021;23(3): 754-762. [PMID: 33269530](https://pubmed.ncbi.nlm.nih.gov/33269530/)
Population: Adults with obesity, no diabetes.
Dose protocol: SC semaglutide titrated to 2.4 mg weekly, 20 weeks.
Key findings: Appetite and ad libitum intake signals aligned with clinical weight findings.
Notes: Supports appetite-directed mechanism but with shorter timeframe.
Paper content
Appetite and ad libitum intake signals aligned with clinical weight findings.
semaglutide-SRC-010Systematic review and meta-analysis of 21 randomized controlled trials.
Sourceopen_in_newAhmad N, Alruwayyes A, Alarjani A, et al. GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2026;105(11):e47994. doi:10.1097/MD.0000000000047994. PMID:41824845.
Population: 7,024 participants across 21 RCTs evaluating GLP-1 receptor agonists for weight management.
Dose protocol: Meta-analysis of 21 RCTs (7,024 participants) evaluating GLP-1 RAs versus placebo for weight loss
Key findings: 78.54% of GLP-1 RA recipients achieved weight loss versus 26.53% placebo (OR 11.37). Tirzepatide and semaglutide ranked highest in efficacy among agents.
Notes: Provides class-level meta-analytic confirmation of semaglutide's position as a top-tier weight loss agent.
Paper content
This meta-analysis pooled 21 RCTs with 7,024 participants to evaluate GLP-1 receptor agonists for weight loss. The results confirmed a strong treatment effect, with 78.54% of participants achieving weight loss on GLP-1 RA versus 26.53% on placebo (OR 11.37). Tirzepatide and semaglutide ranked as the most effective agents in the class. The analysis reinforces the established efficacy of GLP-1 receptor agonists as a class for obesity treatment, with semaglutide consistently among the top performers.
semaglutide-SRC-011Retrospective observational cohort study using propensity score matching.
Sourceopen_in_newPowell WJB, Mazzotti DR, Herrmann SD, et al. Comparison of Semaglutide and Lifestyle Counselling for Weight Loss Using Multi-Site Electronic Health Records. Clin Obes. 2026;16(2):e70076. doi:10.1111/cob.70076. PMID:41830068.
Population: 3,927 adults from multi-site electronic health records, 615 receiving semaglutide and 3,312 receiving lifestyle counseling.
Dose protocol: Semaglutide for 16+ weeks versus lifestyle counseling with 3+ sessions, propensity-matched retrospective analysis
Key findings: Semaglutide users were significantly more likely to achieve 10%+ weight loss than lifestyle counseling alone in both non-diabetic (HR 1.63) and diabetic (HR 2.45) populations.
Notes: Real-world evidence complementing RCT data. Observational design limits causal inference.
Paper content
This real-world retrospective study compared semaglutide therapy with lifestyle counseling alone for weight loss using multi-site electronic health records. After propensity score matching, semaglutide users were significantly more likely to achieve 10% or greater weight loss than those receiving lifestyle counseling only. The advantage was present in both non-diabetic (HR 1.63) and diabetic (HR 2.45) populations. The study provides real-world evidence complementing the RCT data from the STEP program, confirming that semaglutide outperforms standard behavioral weight management in routine clinical practice.